Molecular Therapy
Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2018 impact factor is 8.402.
Molecular Therapy — Methods & Clinical Developments
The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular Therapy – Methods & Clinical Development's 2018 impact factor is 4.875.
Topics of particular interest within the journal's scope include:
Gene vector engineering and production
Methods for targeted genome editing and engineering
Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells
Methods for gene and cell vector delivery
Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine
Analysis of gene and cell vector biodistribution and tracking
Pharmacology/toxicology studies of new and next-generation vectors
Methods for cell isolation, engineering, culture, expansion, and transplantation
Cell processing, storage, and banking for therapeutic application
Preclinical and QC/QA assay development
Translational and clinical scale-up and Good Manufacturing procedures and process development
Clinical protocol development
Computational and bioinformatic methods for analysis, modeling, or visualization of biological data
Negotiating the regulatory approval process and obtaining such approval for clinical trials
Molecular Therapy — Nucleic Acids
Molecular Therapy — Nucleic Acids is an international, open-access journal publishing top-quality basic, translational, and clinical research in the broad fields of nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Subject areas include but are not limited to: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, applications of gene-modifying agents including triplex-forming oligonucleotides and enzymes such as Zn finger nucleases, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy – Nucleic Acid’s 2018 impact factor is 5.919.
Other key topics include:
Applications of DNA-based oligonucleotides and their derivatives
Gene vectors for delivery of RNA-based therapies
Development of nanoparticles and other delivery agents
siRNAs, shRNAs, and miRNAs
Aptamers, ribozymes, and DNAzymes
Peptide nucleic acids
Gene-modifying approaches including enzymes, triplex-forming nucleic acids, and other approaches
Development of new nucleic acid chemistries for altering gene expression
Mechanisms of gene and nucleic acid transfer/transfection
Vector trafficking and biodistribution
Molecular Therapy — Oncolytics
Molecular Therapy—Oncolytics is an international, online-only, open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. While providing a unique forum for work in the burgeoning fields of oncolytic virotherapy, as well as T cell- and stem cell-based therapies, the journal will consider all top-quality, cutting-edge research that employs innovative molecular and cellular approaches that target cancer cells for destruction, whether by viruses,  other microorganisms, vaccination, or transfer of cells and/or genes. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy—Oncolytics will build upon the success of Molecular Therapy and its sibling journals in publishing important peer-reviewed original research and editorial commentary. Molecular Therapy – Oncolytic's 2018 impact factor is 5.710.